MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

35.32 -0.11

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.96

Max

35.45

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -102M
Angestellte	258
EBITDA	-30M -109M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+49.12% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	137M 5.7B
Vorheriger Eröffnungskurs	35.43
Vorheriger Schlusskurs	35.32

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2026, 04:27 UTC

Wichtige Nachrichtenereignisse

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

3. Apr. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 18:30 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3. Apr. 2026, 18:14 UTC

Market Talk

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3. Apr. 2026, 17:50 UTC

Market Talk

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3. Apr. 2026, 17:44 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3. Apr. 2026, 16:50 UTC

Wichtige Nachrichtenereignisse

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3. Apr. 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 16:12 UTC

Ergebnisse

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Equities Roundup: Market Talk

3. Apr. 2026, 15:56 UTC

Market Talk

Wichtige Nachrichtenereignisse

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2026, 15:20 UTC

Wichtige Nachrichtenereignisse

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3. Apr. 2026, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3. Apr. 2026, 14:11 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3. Apr. 2026, 12:56 UTC

Market Talk

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3. Apr. 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 08:01 UTC

Market Talk

Meituan's Profitability Likely to Improve This Year -- Market Talk

3. Apr. 2026, 07:45 UTC

Market Talk

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3. Apr. 2026, 06:17 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3. Apr. 2026, 04:33 UTC

Market Talk

Global Equities Roundup: Market Talk

3. Apr. 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3. Apr. 2026, 04:01 UTC

Market Talk

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

3. Apr. 2026, 02:01 UTC

Market Talk

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

3. Apr. 2026, 01:59 UTC

Market Talk

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

3. Apr. 2026, 01:44 UTC

Market Talk

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

3. Apr. 2026, 01:22 UTC

Market Talk

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

49.12% Vorteil

12-Monats-Prognose

Durchschnitt 52.55 USD 49.12%

Hoch 64 USD

Tief 35 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.